XML 54 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies - Calculation of Net Loss Per Share (Details) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Numerator [Abstract]                      
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (21,506,179) $ (34,134,570) $ (9,479,116) $ (23,085,907) $ (26,233,470) $ (20,759,338) $ (18,704,711) $ (8,042,820) $ (88,205,772) $ (73,740,339) $ (29,187,606)
Adjustment for decrease in fair value of warrant liability                 (806,819) 0 (721,591)
Numerator for use in diluted net loss per share                 $ (89,012,591) $ (73,740,339) $ (29,909,197)
Denominator [Abstract]                      
Weighted average number of common shares outstanding (shares)                 81,777,493 73,214,766 68,198,142
Effect of dilutive potential common shares from warrants (shares)                 140,529 0 167,123
Denominator for use in diluted loss per share (shares)                 81,918,022 73,214,766 68,365,265
Net loss per share, Diluted ($ per share) $ (0.24) $ (0.40) $ (0.13) $ (0.31) $ (0.36) $ (0.28) $ (0.26) $ (0.11) $ (1.09) $ (1.01) $ (0.44)